Crescent Enterprises’ CE-Ventures backs Aptadir Therapeutics in €40 million seed round
CE-Ventures invested in Aptadir Therapeutics’ €40 million seed round announced Sept. 29, 2026, targeting CAP1-FMR1 for Fragile X Syndrome and other programs.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.